NO331072B1 - Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme. - Google Patents

Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.

Info

Publication number
NO331072B1
NO331072B1 NO20013906A NO20013906A NO331072B1 NO 331072 B1 NO331072 B1 NO 331072B1 NO 20013906 A NO20013906 A NO 20013906A NO 20013906 A NO20013906 A NO 20013906A NO 331072 B1 NO331072 B1 NO 331072B1
Authority
NO
Norway
Prior art keywords
immunotherapeutic agent
tumor
composition
well
same
Prior art date
Application number
NO20013906A
Other languages
English (en)
Other versions
NO20013906L (no
NO20013906D0 (no
Inventor
Ralph A Reisfeld
Stephen D Gillies
David A Cheresh
Holger N Lode
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of NO20013906D0 publication Critical patent/NO20013906D0/no
Publication of NO20013906L publication Critical patent/NO20013906L/no
Publication of NO331072B1 publication Critical patent/NO331072B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20013906A 1999-02-12 2001-08-10 Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme. NO331072B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11972199P 1999-02-12 1999-02-12
PCT/US2000/003483 WO2000047228A1 (en) 1999-02-12 2000-02-11 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies

Publications (3)

Publication Number Publication Date
NO20013906D0 NO20013906D0 (no) 2001-08-10
NO20013906L NO20013906L (no) 2001-10-09
NO331072B1 true NO331072B1 (no) 2011-09-26

Family

ID=22385967

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20013906A NO331072B1 (no) 1999-02-12 2001-08-10 Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
NO20101696A NO20101696L (no) 1999-02-12 2010-12-03 Fremgangsmate for behandling av tumorer og metastaser ved bruk av en kombinasjon av anti-angiogenese og immunoterapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20101696A NO20101696L (no) 1999-02-12 2010-12-03 Fremgangsmate for behandling av tumorer og metastaser ved bruk av en kombinasjon av anti-angiogenese og immunoterapi

Country Status (22)

Country Link
US (3) US7115261B1 (no)
EP (1) EP1156823B1 (no)
JP (2) JP4841727B2 (no)
KR (1) KR100704140B1 (no)
CN (1) CN1192796C (no)
AT (1) ATE412433T1 (no)
AU (1) AU776790B2 (no)
BR (1) BR0008161A (no)
CA (1) CA2360106C (no)
CZ (1) CZ303155B6 (no)
DE (1) DE60040651D1 (no)
DK (1) DK1156823T3 (no)
ES (1) ES2313883T3 (no)
HU (1) HU229520B1 (no)
MX (1) MXPA01008110A (no)
NO (2) NO331072B1 (no)
PL (1) PL200919B1 (no)
PT (1) PT1156823E (no)
RU (1) RU2236251C2 (no)
SI (1) SI1156823T1 (no)
SK (1) SK287357B6 (no)
WO (1) WO2000047228A1 (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CN1507354A (zh) * 2001-03-02 2004-06-23 ͨ��ҽ�ƹ�˾ 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
MXPA04002575A (es) * 2001-09-20 2004-06-18 Schering Corp Quimiocinas como adyuventes de respuesta inmune.
RU2312677C9 (ru) * 2001-12-04 2008-03-27 Мерк Патент Гмбх Иммуноцитокины с модулированной селективностью
JP4502641B2 (ja) * 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
GB0217017D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 2
AU2003263964C1 (en) 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CA2497497A1 (en) * 2002-09-04 2004-03-18 Proteinexpress Co., Ltd. Regulators for implantation
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7196061B2 (en) * 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
ES2353967T3 (es) * 2004-07-09 2011-03-08 Chugai Seiyaku Kabushiki Kaisha Anticuerpo anti-glipicano 3 .
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
AU2005326226B2 (en) * 2005-01-31 2010-11-11 Eci, Inc. Immunopotentiating agent
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
JP5020828B2 (ja) * 2005-12-20 2012-09-05 Ｓｂｉバイオテック株式会社 抗ｉｌｔ７抗体
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
DK2769991T3 (en) 2008-01-03 2018-12-10 Scripps Research Inst ANTIBODY TARGETING WITH A MODULAR RECOGNITION AREA
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
CN101983207B (zh) 2008-01-04 2016-01-20 巴克斯特国际公司 抗mif抗体
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
BRPI0921717A2 (pt) * 2008-11-17 2018-10-09 Kobenhavns Univ composto, sequência de peptídeo isolada, composição farmacêutica, uso de um composto, anticorpo, e, método de tratamento
CN102405296A (zh) 2009-03-12 2012-04-04 癌症预防和治疗有限公司 包括基于性别的疾病鉴定、评估、预防以及治疗的用于肺疾病的鉴定、评估、预防以及治疗的方法及其试剂盒
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
CN105412094A (zh) * 2009-07-06 2016-03-23 爱尔皮奥治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
TWI577801B (zh) 2011-02-10 2017-04-11 羅齊克雷雅公司 突變介白素－２多肽
RU2013139267A (ru) * 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
JP2014514572A (ja) * 2011-04-29 2014-06-19 キャンサー・プリヴェンション・アンド・キュア，リミテッド 分類システムおよびそのキットを使用した肺疾患の同定および診断方法
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
AU2012280267B2 (en) 2011-07-06 2016-04-21 Morphosys Ag Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
EP2748195A1 (en) 2011-08-23 2014-07-02 Roche Glycart AG Anti-mcsp antibodies
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
CN102634485A (zh) * 2012-03-15 2012-08-15 上海市浦东新区公利医院 一种表达il-17的胶质瘤细胞株
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
JP6584956B2 (ja) 2012-12-21 2019-10-02 アステラス インスティテュート フォー リジェネレイティブ メディシン 多能性幹細胞から血小板を生産するための方法およびその組成物
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
CN105324124A (zh) 2013-04-19 2016-02-10 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
KR102232153B1 (ko) * 2013-08-20 2021-03-24 머크 샤프 앤드 돔 코포레이션 Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3141603A4 (en) 2014-05-08 2017-12-27 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016086044A1 (en) * 2014-11-24 2016-06-02 University Of Iowa Research Foundation Methods of treating cancer
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN106906184B (zh) * 2017-02-27 2021-04-23 广东昭泰体内生物医药科技有限公司 一种促进肺癌细胞生长的方法
JP2020512978A (ja) * 2017-03-31 2020-04-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法
CA3058481A1 (en) 2017-04-04 2018-10-11 Lung Cancer Proteomics, Llc Plasma based protein profiling for early stage lung cancer prognosis
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CN111562362B (zh) * 2020-04-02 2022-05-20 臻悦生物科技江苏有限公司 一组用于预测三阴乳腺癌免疫联合抗血管生成治疗效果的标志物及其应用和试剂盒
CN111440244B (zh) * 2020-04-09 2021-03-16 诺未科技（北京）有限公司 靶向vegfr2的转移性癌疫苗
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262520A (en) 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DK0574395T3 (da) * 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1997040835A1 (en) * 1996-04-26 1997-11-06 Magainin Pharmaceuticals Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents
CA2256588A1 (en) * 1996-05-31 1997-12-04 The Scripps Research Institute Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis

Also Published As

Publication number Publication date
JP2011207892A (ja) 2011-10-20
PL200919B1 (pl) 2009-02-27
SK287357B6 (sk) 2010-08-09
CZ303155B6 (cs) 2012-05-09
US7833976B2 (en) 2010-11-16
US7115261B1 (en) 2006-10-03
JP4841727B2 (ja) 2011-12-21
HU229520B1 (en) 2014-01-28
ATE412433T1 (de) 2008-11-15
DE60040651D1 (de) 2008-12-11
US20070036751A1 (en) 2007-02-15
EP1156823B1 (en) 2008-10-29
SI1156823T1 (sl) 2009-02-28
EP1156823A1 (en) 2001-11-28
US7365054B2 (en) 2008-04-29
DK1156823T3 (da) 2009-01-19
SK11132001A3 (sk) 2002-06-04
ES2313883T3 (es) 2009-03-16
US20090060864A1 (en) 2009-03-05
CA2360106A1 (en) 2000-08-17
NO20013906L (no) 2001-10-09
CN1346279A (zh) 2002-04-24
WO2000047228A1 (en) 2000-08-17
KR20010102043A (ko) 2001-11-15
NO20101696L (no) 2001-10-09
PT1156823E (pt) 2009-01-08
JP2002536419A (ja) 2002-10-29
CZ20012791A3 (cs) 2002-05-15
RU2236251C2 (ru) 2004-09-20
CA2360106C (en) 2012-10-30
PL350329A1 (en) 2002-12-02
MXPA01008110A (es) 2002-10-23
CN1192796C (zh) 2005-03-16
EP1156823A4 (en) 2003-02-19
AU3228000A (en) 2000-08-29
NO20013906D0 (no) 2001-08-10
KR100704140B1 (ko) 2007-04-09
AU776790B2 (en) 2004-09-23
HUP0200128A2 (en) 2002-05-29
BR0008161A (pt) 2002-05-28

Similar Documents

Publication Publication Date Title
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
NO985150D0 (no) Antigenbindende fragment som sµrlig sporer kreftceller, nukleoid som koder nevnte fragment, samt bruk av dette ved forebygging og pÕvisning av kreft
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
DK1572748T3 (da) Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
DE60018761D1 (de) Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
DK0666868T4 (da) Anvendelse af anti-VEGF-antistoffer til behandling af cancer
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
NO983999D0 (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
DK0910407T3 (da) Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
WO1999002545A3 (en) Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DK1354054T3 (da) Polypeptider der kan binde til CD64, og som omfatter en eller flere heterologe T-celle-epitoper, samt anvendelser deraf
DK199890A (da) Monoklonalt antistof imod aktiverede ras-proteiner, fragmenter deraf, dets anvendelse og hybridoma, som udskiller det
WO2003106478A3 (en) ANTIBODIES BINDING TO ALPHAE INTEGRIN
DK1730196T3 (da) EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
GB9715177D0 (en) Medicament
CY1117275T1 (el) Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους
CY1113344T1 (el) Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων
NO952506L (no) Antistoffpreparater mot homogent minaktivin og anvendelse derav for påvisning av minaktivin i humane kroppsvæsker

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees